Calliditas Therapeutics AB (publ) (NASDAQ:CALT) Posts Quarterly Earnings Results, Misses Expectations By $0.74 EPS

Calliditas Therapeutics AB (publ) (NASDAQ:CALT) issued its quarterly earnings results on Thursday. The company reported ($0.88) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.74), Yahoo Finance reports. The firm had revenue of $28.43 million during the quarter, compared to analyst estimates of $35.78 million. Calliditas Therapeutics AB (publ) had a negative return on equity of 133.08% and a negative net margin of 40.19%.

Calliditas Therapeutics AB (publ) Stock Down 1.5 %

Calliditas Therapeutics AB (publ) stock traded down $0.33 during midday trading on Friday, reaching $22.42. The company’s stock had a trading volume of 13,209 shares, compared to its average volume of 3,506. Calliditas Therapeutics AB has a 52-week low of $15.25 and a 52-week high of $29.30. The stock has a market capitalization of $667.89 million, a P/E ratio of -13.67 and a beta of 1.50. The company has a debt-to-equity ratio of 2.89, a current ratio of 3.13 and a quick ratio of 3.08. The stock’s 50-day simple moving average is $20.60 and its 200-day simple moving average is $21.15.

Analyst Ratings Changes

Separately, HC Wainwright lowered their price target on shares of Calliditas Therapeutics AB (publ) from $50.00 to $45.00 and set a “buy” rating on the stock in a report on Friday.

Calliditas Therapeutics AB (publ) Company Profile

Calliditas Therapeutics AB (publ), a commercial-stage bio-pharmaceutical company, focused on identifying, developing, and commercializing novel treatments in orphan indications with an initial focus on renal and hepatic diseases with significant unmet medical needs in the United States, Europe, and Asia.